Search results

660 results

Sorted by Relevance . Sort by Date

In development Remove In development filter
Proposed Remove Proposed filter
Technology appraisal guidance Remove Technology appraisal guidance filter
Diagnostics guidance Remove Diagnostics guidance filter
Public health guidelines Remove Public health guidelines filter
Safe staffing guidelines Remove Safe staffing guidelines filter
Social care guidelines Remove Social care guidelines filter

Disabled children and young people up to 25 with severe complex needs: integrated service delivery and organisation across health, social care and education

In development [GID-NG10113] Expected publication date: 19 January 2022

Type

NICE guideline

Status

In development
Adults with complex needs: social work interventions including assessment, care management and support

In development [GID-NG10145] Expected publication date: 27 April 2022

Type

NICE guideline

Status

In development
Advocacy services for adults with health and social care needs

In development [GID-NG10156] Expected publication date: TBC

Type

NICE guideline

Status

In development
Integrated sensor-augmented pump therapy systems for managing blood glucose levels in type 1 diabetes (update of DG21) (provisional title)

In development [GID-DG10042] Expected publication date: 13 April 2022

Type

Diagnostics guidance

Status

In development
PredictSURE IBD and IBDX to guide treatment of Crohn's disease

In development [GID-DG10029] Expected publication date: TBC

Type

Diagnostics guidance

Status

In development
Perineal biopsy devices for diagnosis of prostate cancer in people with suspected prostate cancer [provisional title]

In development [GID-DG10043] Expected publication date: TBC

Type

Diagnostics guidance

Status

In development
Exploratory economic modelling of SARS-CoV-2 viral detection point of care tests and serology tests

In development [GID-DG10038] Expected publication date: 06 January 2021

Type

Diagnostics guidance

Status

In development
SeHCAT (tauroselcholic [75 selenium] acid) for the investigation of bile acid diarrhoea

In development [GID-DG10039] Expected publication date: 17 November 2021

Type

Diagnostics guidance

Status

In development
PlGF-based testing to help diagnose suspected pre-eclampsia (Update of DG23)

In development [GID-DG10040] Expected publication date: 17 November 2021

Type

Diagnostics guidance

Status

In development
Quantitative faecal immunochemical tests to guide colorectal cancer pathway referral for people with a change in bowel habit or abdominal pain

In development [GID-DG10036] Expected publication date: TBC

Type

Diagnostics guidance

Status

In development
QAngio XA 3D QFR and CAAS vFFR imaging software for assessing coronary stenosis during invasive coronary angiography

In development [GID-DG10034] Expected publication date: TBC

Type

Diagnostics guidance

Status

In development
EarlyCDT Lung for lung cancer risk classification of solid pulmonary nodules

In development [GID-DG10041] Expected publication date: 23 February 2022

Type

Diagnostics guidance

Status

In development
Managing common infections - antimicrobial prescribing guidelines

In development [GID-NG10050] Expected publication date: TBC

Type

NICE guideline

Status

In development
Tobacco: preventing uptake, promoting quitting and treating dependence (update)

In development [GID-NG10086] Expected publication date: 01 September 2021

Type

NICE guideline

Status

In development
Social, emotional and mental wellbeing in primary and secondary education

In development [GID-NG10125] Expected publication date: 17 May 2022

Type

NICE guideline

Status

In development
Reducing sexually transmitted infections

In development [GID-NG10142] Expected publication date: 09 February 2022

Type

NICE guideline

Status

In development
Looked-after children and young people

In development [GID-NG10121] Expected publication date: 27 September 2021

Type

NICE guideline

Status

In development
Vaccine uptake in the general population

In development [GID-NG10139] Expected publication date: 06 April 2022

Type

NICE guideline

Status

In development
Mental wellbeing at work

In development [GID-NG10140] Expected publication date: 15 December 2021

Type

NICE guideline

Status

In development
Integrated health and social care for people experiencing homelessness

In development [GID-NG10170] Expected publication date: 16 March 2022

Type

NICE guideline

Status

In development
Olaparib with abiraterone for untreated hormone-relapsed metastatic prostate cancer [ID3920 ]

Proposed [GID-TA10802] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Amcenestrant for treating ER-positive, HER2-negative advanced breast cancer after hormonal therapy [ID3919]

Proposed [GID-TA10803] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after trastuzumab or a taxane [ID3909]

Proposed [GID-TA10804] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Tideglusib for treating congenital myotonic dystrophy type 1 [ID3915 ]

Proposed [GID-TA10791] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Mitapivat for treating pyruvate kinase deficiency [ID3914 ]

Proposed [GID-TA10795] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Maribavir for treating refractory or resistant cytomegalovirus infection after transplant [ID3900]

Proposed [GID-TA10792] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Tezepelumab for maintenance treatment of uncontrolled severe asthma in people aged 12 and over [ID3910]

Proposed [GID-TA10796] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Difelikefalin for treating pruritis in people having haemodialysis [ID3890 ]

Proposed [GID-TA10793] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Omecamtiv mecarbil for treating chronic heart failure with reduced ejection fraction [ID3912 ]

Proposed [GID-TA10797] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Brolucizumab for treating diabetic macular oedema [ID3902]

Proposed [GID-TA10794] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Faricimab for treating diabetic macular oedema [ID3899]

Proposed [GID-TA10798] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Faricimab for treating wet age-related macular degeneration [ID3898 ]

Proposed [GID-TA10799] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Imetelstat for treating relapsed or refractory transfusion-dependent myelodysplastic syndromes [ID3922]

Proposed [GID-TA10800] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Cemiplimab for treating recurrent or metastatic cervical cancer [ID3921]

Proposed [GID-TA10801] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Olipudase alfa for treating Niemann-Pick disease types A and B [ID3913 ]

Proposed [GID-TA10788] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Timrepigene emparvovec for treating choroideremia [ID3916]

Proposed [GID-TA10787] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Pembrolizumab for adjuvant treatment of resected stage 2 melanoma with high risk of recurrence [ID3908 ]

Proposed [GID-TA10786] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Polatuzumab vedotin with R-CHP for untreated diffuse large B-cell lymphoma [ID3901 ]

Proposed [GID-TA10785] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Pembrolizumab for adjuvant treatment of resected non-small-cell lung cancer [ID3907 ]

Proposed [GID-TA10784] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Pegunigalsidase alfa for treating Fabry disease [ID3904]

Proposed [GID-TA10790] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Leriglitazone for treating X-linked andrenoleukodystrophy [ID 3903]

Proposed [GID-TA10789] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Durvalumab with chemoradiation for treating unresectable locally advanced non-small-cell lung cancer [ID3906]

Proposed [GID-TA10783] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Nitisinone for treating alkaptonuria [ID2691]

Proposed [GID-TA10659] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Filgotinib for treating moderately to severely active ulcerative colitis [ID3736]

Proposed [GID-TA10600] Expected publication date: 22 December 2021

Type

Technology appraisal guidance

Status

Proposed
Treosulfan with fludarabine for non-malignant disease before allogeneic stem cell transplant [ID1540]

Proposed [GID-TA10453] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Dulaglutide for treating type 2 diabetes [ID1451]

Proposed [GID-TA10439] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Gosuranemab for treating progressive supranuclear palsy [ID1607]

Proposed [GID-TA10553] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Autologous haematopoietic stem cell transplantation for treating multiple sclerosis (ID1111)

Proposed [GID-TA10306] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Lasmiditan for treating acute migraine [ID3759]

Proposed [GID-TA10807] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Abemaciclib for adjuvant treatment of hormone receptor-positive, HER2-negative, node-positive early breast cancer [ID3857]

Proposed [GID-TA10749] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed